Inovio Pharmaceuticals Phase 3 HPV Immunotherapy Vaccine Receives “Best Therapeutic Vaccine” at World Vaccine Congress

Inovio Pharmaceuticals Phase 3 HPV Immunotherapy Vaccine Receives “Best Therapeutic Vaccine” at World Vaccine Congress

Inovio Pharmaceuticals announced  VGX-3100, its Phase 3 immunotherapy to treat cervical dysplasia, was selected for the “Best Therapeutic Vaccine” award at the World Vaccine Congress held in Washington, D.C. Each year, the Vaccine Industry Excellence (ViE)...

Pin It on Pinterest